崔荟楠++唐晓红++王立涛++槐梅

DOI：10.16662/j.cnki.1674-0742.2017.20.110

[摘要] 目的 观察分析GP全身化疗联合吡柔比星热灌注治疗晚期膀胱癌的临床疗效及不良反应。方法 方便选取2015年4月—2016年4月在赤峰市第二医院收治的64例晚期膀胱癌患者作为观察对象，并随机分为观察组（32例）和对照组（32例），对照组患者给予吉西他滨+顺铂（GP）方法进行全身化疗，观察组患者在对照组基础上联合吡柔比星热灌注化疗，比较两组患者的临床疗效及不良反应发生率。 结果 观察组临床有效率（75.00%）及不良反应情况明显优于对照组（46.88%）（P<0.05）。 结论 GP全身化疗联合吡柔比星热灌注对治疗晚期膀胱癌患者的临床疗效有明显的改善，提高了患者的生活质量，并未见及未增加明显相关的不良反应，故值得认可和推广。

[关键词] 全身化疗；吡柔比星；晚期膀胱癌；临床疗效；不良反应

[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2017）07（b）-0110-03

Analysis of Clinical Curative Effect and Adverse Reactions of GP General Chemotherapy and Pirarubicin Hyperthermal Perfusion Therapy for Advanced Bladder Cancer

CUI Hui-nan1， TANG Xiao-hong1， WANG Li-tao1， HUAI Mei2

1.Department of Oncology Medicine， Chifeng Second Hospital， Chifeng， Inner Mongolia， 024000 China；2.Department of Cardio-Thoracic Surgery， Huabei Oilfield General Hospital， Cangzhou， Hebei Province， 062552 China

[Abstract] Objective To observe and analyze the clinical curative effect and adverse reactions of GP general chemotherapy and pirarubicin hyperthermal perfusion therapy for advanced bladder cancer. Methods 64 cases of patients with advanced bladder cancer admitted and treated in our hospital from April 2015 to April 2016 were convenient selected and randomly divided into two groups with 32 cases in each， the control group adopted the gemcitabine and GP general chemotherapy， while the observation group adopted the pirarubicin hyperthermal perfusion therapy on the basis of the control group， and the clinical curative effect and incidence rate of adverse reactions were compared between the two groups. Results The clinical effective rate and adverse reactions in the observation group were better than those in the control group（75.00% vs 46.88%）（P<0.05）. Conclusion The clinical curative effect of GP general chemotherapy and pirarubicin hyperthermal perfusion therapy for advanced bladder cancer is obviously improved， which improves the quality of life of patients without obvious adverse reactions， and it is worth recognition and promotion.

[Key words] General chemotherapy； Pirarubicin； Advanced bladder cancer； Clinical curative effect； Adverse reactions

膀胱癌是泌尿系統最常见的恶性肿瘤，且发病率位居泌尿系统恶性肿瘤的第一位[1]，目前临床上对该病发病原因尚不清楚，多数相关学者研究认为往往与接触致癌物如萘胺，联苯胺等有关，更常见的生活用品染料及橡胶、塑料制品和油漆、洗涤剂等均有潜在的致癌危险，人们生活习惯如吸烟不仅对呼吸系统有害，也会提高膀胱癌的发生率。还可以由某些疾病如膀胱白斑及腺性膀胱炎、尿道结石和尿潴留等也可能会诱发膀胱癌[2]。据我国有关数据统计，男女的膀胱癌发生率约占5：2，多发生在年龄51～70岁的群体[3]。临床上多采用膀胱内灌注化疗或全身化疗等治疗控制膀胱癌细胞的扩散。为此常用化疗药物有吉西他滨和顺铂、吡柔比星等，其中吡柔比星可干扰DNA和mRNA合成，在细胞增殖周期中阻断细胞进入G1期而干扰瘤细胞分裂和抑制肿瘤生长，所以具有很强的抗癌活性；……